Connecting the Dots Across Pharma’s Siloed Market Access Analytics

In recent conversations with pharma leaders across the Reuters Pharma ecosystem, one theme surfaced repeatedly: organizations are becoming increasingly sophisticated at modeling financial outcomes, yet far less disciplined at validating whether those outcomes are commercially executable.

Financial viability and commercial feasibility sound similar. In practice, they are entirely different tests.

A payer deal gets approved. The economics work, the rebate thresholds are acceptable, and the projected formulary access improvement appears strong enough to justify the investment.

Months later, commercial teams are struggling to deliver the patient volume that the original model assumed.

Not because the analytics were wrong. Because nobody asked whether the organization could realistically execute the growth scenario the analytics required.

That distinction sits at the center of one of pharma’s most underexamined market access blind spots. Across the industry, payer agreements continue to undergo rigorous financial viability testing, while commercial feasibility testing remains surprisingly absent, even in high-stakes decisions with significant revenue exposure.

The Test Most Organizations Still Don’t Run 

The issue is not analytical immaturity. Most large pharma organizations already have sophisticated frameworks capable of estimating rebate exposure, formulary impact, and projected market share movement with considerable precision. 

The issue is structural. Financial models are designed to validate whether a deal works economically. They are rarely designed to test what operational conditions must exist for those assumptions to become commercially real.

If a payer agreement assumes a brand must dramatically increase new patient acquisition, the critical question cannot stop at whether the projected economics support the deal.

The more important question is whether the organization can physically reach the  prescribers required to generate that growth.

That is not a pricing question. It is an execution question

In one analysis, nearly half of the projected opportunity tied to a signed payer agreement depended on prescribers the organization was not actively calling on. The financial assumptions had already been approved. The commercial infrastructure required to support them had not. 

That gap creates downstream consequences that most organizations only discover after the deal is already operational: insufficient field coverage, disconnected pull-through strategy, fragmented non-personal promotion, and unrealistic market share assumptions embedded inside commercial forecasts.

The Organizational Problem Disguised as an Analytics Problem

One of the industry’s biggest misconceptions is the belief that this is fundamentally a data problem.

The required data already exists across the enterprise. Contracting teams own rebate and payer data. Commercial organizations manage prescription trends, targeting infrastructure, and engagement analytics. Market access teams understand access dynamics, while commercial operations teams understand field realities. 

The real issue is that these analyses terminate inside functional silos because no single group owns continuity between payer strategy and commercial execution.

Most organizations are not lacking analytics capability. They are lacking connective tissue.

That tension becomes even more complex because the challenge is organizational as much as analytical. Pricing and contracting teams are understandably protective of commercially sensitive deal structures. Commercial teams are resistant to disconnected targeting recommendations that fail to align with field realities.

As a result, many cross-functional analytics initiatives fail not because the analytics themselves are weak, but because organizational trust,  access, and operational alignment become the real bottlenecks. 

Where the Market Access COE Changes the Equation

This is precisely where we believe the Market Access Analytics Center of Excellence becomes strategically important.

At CustomerInsights.AI, our perspective has increasingly been that the value of the COE model is not in creating entirely new analytics. It is in creating continuity between analyses that currently stop at functional boundaries.

That distinction matters because the future of market access will depend less on generating more dashboards and more on operationally connecting payer strategy, pull-through execution, attribution modeling, prescriber coverage mapping, and post-deal performance measurement.

The most effective COEs do not challenge ownership. They augment the teams already responsible for execution.

That subtle positioning shift changes the organizational dynamic entirely. Instead of forcing collaboration through governance mandates, the model creates analytical value for the functions holding the data.

One particularly important capability is attribution modeling. Commercial teams may resist another list of physician targets, but they pay close attention when analytics  demonstrate  which engagement strategies are genuinely influencing behavior and producing measurable return. 

Insight earns organizational access faster than oversight ever will.

The Strategic Shift Pharma Can No Longer Ignore

As pharma organizations become increasingly specialized, fragmented, and data-intensive, the competitive advantage will not come from building larger analytics infrastructures alone.

It will come from connecting decisions that currently operate independently across contracting, market access, commercial operations, and field execution.

The organizations that succeed will likely be the ones capable of maintaining continuity between payer assumptions and commercial reality before, during, and after a deal is signed.

For your last major payer agreement, what percentage of projected patient opportunity depended on prescribers outside your current commercial reach?

If that number does not exist, the organization may not have validated execution feasibility at all.

It may simply have validated financial assumptions in isolation.

And increasingly, that may be one of the most expensive blind spots in modern pharma commercialization.